Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

Q&A med Zealand Pharma, 25 September kl 16.00 Læs mere her
      
side 1 / 251
Opret nyt indlæg

Teknisk analyse på laksesektoren
16/9 15:07 Helge Larsen/PI-redaktør Svar: 0

GENMAB: 139 studier med Daratumumab
14/9 12:40 Helge Larsen/PI-redaktør Svar: 0

Gode resultater for for Genmabs Ofatumumab ..
13/9 15:08 Helge Larsen/PI-redaktør Svar: 0

Genmab baggrund til ipad'en
10/9 16:29 peter12 Svar: 0

GENMAB - Ny strategisk aftale med Tempus
9/9 15:50 Helge Larsen/PI-redaktør Svar: 0

Vi tager på TA-rundtur i gamingindustrien
9/9 10:18 Markettimer Svar: 0

Bliv en bedre biotekinvestor
7/9 17:40 Helge Larsen/PI-redaktør Svar: 1

Zymeworks i ATH
6/9 08:19 Sukkeralf Svar: 0

Zealand Pharma - Private placement DKK 559.6
5/9 08:06 Helge Larsen/PI-redaktør Svar: 0

Kurstriggere i Genmab i sep. 2019
3/9 11:24 Helge Larsen/PI-redaktør Svar: 0

Aktiejagt i skandinavien
3/9 10:58 Markettimer Svar: 3

Giftige laks - hvad er op og ned??
30/8 16:54 sarkath Svar: 7

Dette er en test
30/8 12:13 Ralph Rezende Larsen Svar: 0

Norwegian
29/8 13:40 larsen Svar: 0

Langsigtet investering
27/8 19:28 claus andreassen Svar: 0

Flotte kursstigninger i LPG-sektoren i 2019
27/8 11:27 Helge Larsen/PI-redaktør Svar: 7

3 spændende TA-aktier til næste uge.
23/8 14:17 Hans-Henrik Nielsen Svar: 2

Vi tager et TA-kig på 10 store US-aktier
19/8 11:58 Hans-Henrik Nielsen Svar: 0

Går GE konkurs i år?
18/8 09:10 Hans-Henrik Nielsen Svar: 0

Et TA-kig på mulige vindere og store tabere
16/8 11:15 Hans-Henrik Nielsen Svar: 0

Zealand Pharma - Halvårsrapport 2019
15/8 16:46 Helge Larsen/PI-redaktør Svar: 0

Laksesektoren - "En tryg investering"
15/8 16:19 Helge Larsen/PI-redaktør Svar: 0

Spændende aktier i et svært marked
12/8 10:45 Hans-Henrik Nielsen Svar: 0

Tesla - skal man slå til nu
8/8 12:12 Kingoo1 Svar: 1

Hvordan undgår jeg panik i et rødt marked?
6/8 09:04 Hans-Henrik Nielsen Svar: 7

DNO - BWO - BWLPG - QEC
4/8 14:56 Mn69 Svar: 1

Norske aktier i Mio-klubben på Radio24/7
1/8 12:37 Helge Larsen/PI-redaktør Svar: 0

Et TA-kig på 6 aktier fra Skandinavien og U..
1/8 09:54 Hans-Henrik Nielsen Svar: 0

Christian Hansens store fald, Nye tider?
31/7 11:30 Krabbovich Svar: 0

Revidering af USA's BNP - Hvad fortæller de..
27/7 12:20 Hans-Henrik Nielsen Svar: 1

Carlsberg fortsætter fantastisk TA-trend
26/7 10:44 Hans-Henrik Nielsen Svar: 3

Lagerbeskatning
25/7 13:37 Spekulant.dk Svar: 3

Guld
24/7 10:27 WBA Svar: 0

Så bliver der købt spændende aktier til TA-..
22/7 11:10 Hans-Henrik Nielsen Svar: 2

Skandinaviske bankaktier ETF'er
21/7 13:05 N_Nielsen Svar: 2

Genovis AB
12/7 09:31 Interface Svar: 0

En hurtig TA-rundtur i 5 spændende aktier
11/7 21:35 Hans-Henrik Nielsen Svar: 0

Alligator Bioscienes - Halvårsrapport 2019
11/7 09:42 Helge Larsen/PI-redaktør Svar: 0

Så rykker laksene igen!
8/7 14:16 Hans-Henrik Nielsen Svar: 0

Factor olympics H1 2019
3/7 10:11 TeamGarlic Svar: 0

Hvorfor skal en TA'er også kigge på nøgleta..
2/7 10:01 Hans-Henrik Nielsen Svar: 1

Et kig på ETF'er, passiv investering og Ray..
26/6 10:58 Hans-Henrik Nielsen Svar: 2

Hvad siger TA og FA om laksesektoren
24/6 11:27 Hans-Henrik Nielsen Svar: 0

Darzalex 2019 estimat
19/6 10:20 peter12 Svar: 0

Her gennemgår jeg min TA-portefølje
19/6 09:33 Hans-Henrik Nielsen Svar: 4

Ambu vs. Munters Group - Hvad er forskellen
14/6 09:37 Hans-Henrik Nielsen Svar: 0

FED skaber rod i markedet
12/6 21:37 Hans-Henrik Nielsen Svar: 0

NOVO´s Semaglutide med flotte data fase 3
9/6 15:05 Helge Larsen/PI-redaktør Svar: 0

Vi kigger på toldkrig med Mexico, renteudme..
9/6 12:09 Hans-Henrik Nielsen Svar: 0

Et TA-aktiekig i et volatilt marked
4/6 19:38 Hans-Henrik Nielsen Svar: 0


GENMAB - Ny strategisk aftale med Tempus

  



Genmab and Tempus Enter into Strategic Collaboration Agreement
September 9, 2019 at 3:07 PM CEST



Copenhagen, Denmark, September 9, 2019

Genmab and Tempus sign agreement to research and develop novel targets

Genmab A/S (Nasdaq: GMAB) announced today that it has entered into a strategic collaboration agreement with Tempus, a privately-owned technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The multi-year collaboration will combine Tempus' sequencing capabilities and industry-leading platform of integrated clinical and molecular data with Genmab's state-of-the-art translational, biomarker and target discovery expertise. The companies will work together, based upon novel insights identified by Genmab, to advance new disease targets and biomarkers that may have the potential to generate new treatments in oncology.

This new strategic collaboration builds upon existing service agreements between the companies. Under the terms of the collaboration agreement, the companies will jointly work on research projects that are identified by Genmab to explore novel product concepts and biomarkers. For any resulting products, Genmab will lead all development and commercial activities. Tempus will be eligible for undisclosed milestones and royalties from Genmab and will also have the option to fund part of product development programs in exchange for increased royalty payments due to Tempus under the agreement.

"Tempus has built the world's largest library of clinical and molecular data, is a leader in the field of personalized medicine and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Today's news does not impact Genmab's 2019 Financial Guidance.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with core sites in Utrecht, the Netherlands and Princeton, New Jersey, U.S.


Contact:
Marisol Peron, Corporate Vice President, Communications & Investor Relations
T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:
Andrew Carlsen, Senior Director, Investor Relations
T: +45 3377 9558; E: acn@genmab.com

Helge Larsen/PI-redaktør 0 76976 9/9 2019 15:50 STEM OP SVAR




side 1 / 251
Opret nyt indlæg